Latest Trastuzumab Stories
The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients.
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease.
New research has found that breast cancer tumors change their hormonal status throughout the course of disease, whereas the decision about the most effective treatment for the patient is usually only based on one biopsy of the primary tumor.
The first randomized trial to investigate the use of trastuzumab emtansine (T-DM1) – an antibody-guided drug – for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.